The observed differential mRNA and protein expression levels of GPX4 and TfR1 in vitro may bear clinical relevance when considering factors such as tumor heterogeneity and the wide-ranging therapeutic response of thyroid tumors harboring diverse mutational signatures. This evidence concerns the gene TFRC and thyroid tumor.